Fragmento

Dear Editor: Recently, the standard of care (SoC) of chronic hepatitis C virus (HCV) infection has changed, and HCV treatment has entered a new era with the introduction of direct-acting antiviral agents (DAAs). Combination therapy with pegylated interferon (pegIFN) and ribavirin (RBV) and the two first generation NS3/4A protease inhibitors (PI) –telaprevir (TVR) and boceprevir (BOC)– has been approved in many countries.1-3 Although these combinations significantly increase sustained virological response (SVR) rates, they also increase adverse events rates. Previously well known adverse events related to pegIFN/RBV increases their frequency and severity, and new adverse events related to PIs develop. Anemia and dysgeusia are more frequent in patients treated with BOC and anemia, pruritus, rash and anorectal symptoms are more frequent in patients treated with TVR, when compared with PegIFN/RBV alone. With PIs therapy incorporated in clinical practice, new adverse events may be expected. Another new concern appears with HCV therapy triple therapy: drug-drug interaction; with the risk of increasing adverse events and decreasing SVR rates.

Palabras clave:

2013-10-04   |   577 visitas   |   Evalua este artículo 0 valoraciones

Vol. 12 Núm.5. Septiembre-Octubre 2013 Pags. 837-838 Ann Hepatol 2013; 12(5)